Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Idiopatisk lungefibrose og interstitiell lungesykdom Prospektive utfallsregister (IPF/ILD-PRO)

9. november 2026 oppdatert av: Duke University

Idiopatisk lungefibrose prospektive utfall (IPF-PRO) og kronisk fibroserende interstitiell lungesykdom med progressive fenotype prospektive utfall (IPF-PRO/ILD-PRO) register

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

Studieoversikt

Detaljert beskrivelse

This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.

Studietype

Observasjonsmessig

Registrering (Antatt)

3000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35294
        • Rekruttering
        • University of Alabama - Birmingham
        • Hovedetterforsker:
          • Tejaswini Kulkarni, MD
        • Ta kontakt med:
    • Arizona
      • Tucson, Arizona, Forente stater, 85721
        • Rekruttering
        • University of Arizona
        • Hovedetterforsker:
          • Sally A Suliman, MD
        • Ta kontakt med:
    • California
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • University of Southern California
        • Ta kontakt med:
        • Hovedetterforsker:
          • Toby Maher, MD
      • Los Angeles, California, Forente stater, 90024
        • Rekruttering
        • University of California - Los Angeles
        • Hovedetterforsker:
          • John Belperio, MD
        • Ta kontakt med:
      • Stanford, California, Forente stater, 94305
        • Rekruttering
        • Stanford University
        • Hovedetterforsker:
          • Rishi Raj, MD
        • Ta kontakt med:
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • University of Colorado
        • Hovedetterforsker:
          • Joyce Lee, MD
        • Ta kontakt med:
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06520
        • Rekruttering
        • Yale University
        • Hovedetterforsker:
          • Mridu Gulati, MD
        • Ta kontakt med:
    • Florida
      • Gainesville, Florida, Forente stater, 32610-3175
        • Rekruttering
        • University of Florida
        • Ta kontakt med:
        • Hovedetterforsker:
          • Diana Gomez Manjarres, MD
      • Tampa, Florida, Forente stater, 33606
        • Rekruttering
        • University of South Florida
        • Hovedetterforsker:
          • Jose D Herazo-Maya, MD
        • Ta kontakt med:
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Emory University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Srihari Veeraraghavan, MD
      • Austell, Georgia, Forente stater, 30106
        • Rekruttering
        • Piedmont Healthcare
        • Hovedetterforsker:
          • Amy Case, MD
        • Ta kontakt med:
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
        • Rekruttering
        • University of Chicago
        • Hovedetterforsker:
          • Mary Strek, MD
        • Ta kontakt med:
      • Evanston, Illinois, Forente stater, 60611
        • Rekruttering
        • Northwestern University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bradford Bemiss, MD
      • Maywood, Illinois, Forente stater, 60153
        • Rekruttering
        • Loyola University Health System
        • Hovedetterforsker:
          • Daniel Dilling, MD
        • Ta kontakt med:
    • Kansas
      • Kansas City, Kansas, Forente stater, 66160
        • Avsluttet
        • University of Kansas
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536
        • Rekruttering
        • University of Kentucky
        • Hovedetterforsker:
          • Girish Nair, MD
        • Ta kontakt med:
    • Louisiana
      • New Orleans, Louisiana, Forente stater, 70112
        • Rekruttering
        • Tulane University
        • Hovedetterforsker:
          • Joe Lasky, MD
        • Ta kontakt med:
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Aktiv, ikke rekrutterende
        • University of Michigan
      • Detroit, Michigan, Forente stater, 48202
        • Rekruttering
        • Henry Ford Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Asif Abdul Hameed, MD
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • Rekruttering
        • University of Minnesota
        • Ta kontakt med:
        • Hovedetterforsker:
          • Hyum Kim, MD
    • Mississippi
      • Jackson, Mississippi, Forente stater, 39216
        • Rekruttering
        • University of Mississippi Medical Center
        • Hovedetterforsker:
          • Kimberly Dobbs, MD
        • Ta kontakt med:
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University
        • Hovedetterforsker:
          • Tonya Russell, MD
        • Ta kontakt med:
    • New York
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Weill Medical College of Cornell University
        • Hovedetterforsker:
          • Kerri Aronson, MD
        • Ta kontakt med:
      • New York, New York, Forente stater, 10016
        • Aktiv, ikke rekrutterende
        • NYU Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27514
        • Rekruttering
        • UNC Chapel Hill
        • Hovedetterforsker:
          • Jason Lobo, MD
        • Ta kontakt med:
      • Durham, North Carolina, Forente stater, 27705
        • Rekruttering
        • Duke University
        • Hovedetterforsker:
          • Lake Morrison, MD
        • Ta kontakt med:
      • Greensboro, North Carolina, Forente stater, 27403
        • Rekruttering
        • Pulmonix LLC
        • Hovedetterforsker:
          • Murali Ramaswamy, MD
        • Ta kontakt med:
      • Wilmington, North Carolina, Forente stater, 28401
        • Avsluttet
        • PMG Research
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Rekruttering
        • Wake Forest Baptist Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Andrew Namen, MD
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45267
        • Aktiv, ikke rekrutterende
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, Forente stater, 44195
        • Rekruttering
        • Cleveland Clinic
        • Hovedetterforsker:
          • Brian Southern, MD
        • Ta kontakt med:
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • The Ohio State University
        • Ta kontakt med:
        • Hovedetterforsker:
          • John Odackal
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • Rekruttering
        • University of Oklahoma
        • Hovedetterforsker:
          • Jad Kebbe, MD
        • Ta kontakt med:
    • Oregon
      • Portland, Oregon, Forente stater, 97220
        • Rekruttering
        • Oregon Clinic
        • Hovedetterforsker:
          • David Hotchkin, MD
        • Ta kontakt med:
    • Pennsylvania
      • Hershey, Pennsylvania, Forente stater, 17033
        • Rekruttering
        • Penn State College of Medicine - Hershey
        • Hovedetterforsker:
          • Rebecca Bascom, MD
        • Ta kontakt med:
      • Philadelphia, Pennsylvania, Forente stater, 19140
      • Philadelphia, Pennsylvania, Forente stater, 19144
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29425
        • Rekruttering
        • Medical University of South Carolina
        • Hovedetterforsker:
          • Timothy Whelan, MD
        • Ta kontakt med:
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
        • Rekruttering
        • Vanderbilt University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Justin Hewlett, MD
    • Texas
      • Dallas, Texas, Forente stater, 75235
        • Rekruttering
        • University of Texas Southwestern
        • Hovedetterforsker:
          • John Fitzgerald, MD
        • Ta kontakt med:
      • Dallas, Texas, Forente stater, 75246
        • Rekruttering
        • Baylor University Medical Center at Dallas
        • Hovedetterforsker:
          • Yolanda Mageto, MD
        • Ta kontakt med:
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Baylor College of Medicine
        • Hovedetterforsker:
          • Ivan Rosas, MD
        • Ta kontakt med:
      • Houston, Texas, Forente stater, 77030
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • The University of Texas Health Science Center At Houston
        • Hovedetterforsker:
          • Rodeo Abrencillo, MD
        • Ta kontakt med:
    • Utah
      • Salt Lake City, Utah, Forente stater, 84108
        • Rekruttering
        • University of Utah
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mary Beth Langer, MD
      • Salt Lake City, Utah, Forente stater, 84111
        • Rekruttering
        • Intermountain Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Erin Blackstock, MD
    • Vermont
      • Colchester, Vermont, Forente stater, 05446
        • Aktiv, ikke rekrutterende
        • University of Vermont Lung Center
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
        • Aktiv, ikke rekrutterende
        • University from Virginia
      • Falls Church, Virginia, Forente stater, 22042-3307
        • Rekruttering
        • Inova Health Care Services
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jared Wilkinson, MD
    • Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Aktiv, ikke rekrutterende
        • The Medical College of Wisconsin

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.

Beskrivelse

Inclusion Criteria:

  • Willing and able to provide informed consent

  • Established a new diagnosis (within 12 months) of IPF by the enrolling center.

  • Age 21 years or older, or

  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:

    • Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.

    • Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):

      • decline in FVC % predicted (% pred) based on ≥10% relative decline
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
      • decline in DLCO % pred based on≥ 10% relative decline
      • worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.

The relative decline for FVC % predicted is calculated using the formula:

Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.

The relative decline for DLCO % predicted is calculated using the formula:

Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening

Exclusion Criteria:

  • Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
  • For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry

Subjects with a non-IPF ILD diagnosis

Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

New Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Tidsramme: End of Study (3 years after last patient will be enrolled)

Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.

End of Study (3 years after last patient will be enrolled)
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Tidsramme: End of Study (3 years after last patient will be enrolled)

Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD

End of Study (3 years after last patient will be enrolled)
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Tidsramme: End of Study (3 years after last patient will be enrolled)

Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL).

End of Study (3 years after last patient will be enrolled)
Blood samples for future research.
Tidsramme: End of Study (3 years after last patient will be enrolled)

Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions.

End of Study (3 years after last patient will be enrolled)
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Tidsramme: End of Study (3 years after last patient will be enrolled)

Collect longitudinal HRCT images for future research

End of Study (3 years after last patient will be enrolled)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Data on management practices compared to existing guidelines.
Tidsramme: End of Study (3 years after last patient will be enrolled)

Compare disease-specific management practices with existing guidelines.

End of Study (3 years after last patient will be enrolled)
Data on center-specific practices on outcomes.
Tidsramme: End of Study (3 years after last patient will be enrolled)

Determine the influence of center-specific practices on patient outcomes.

End of Study (3 years after last patient will be enrolled)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Scott Palmer, MD, Duke Clinical Research Institute, Duke University

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. juni 2014

Primær fullføring (Antatt)

1. januar 2028

Studiet fullført (Antatt)

1. januar 2031

Datoer for studieregistrering

Først innsendt

31. juli 2013

Først innsendt som oppfylte QC-kriteriene

1. august 2013

Først lagt ut (Antatt)

5. august 2013

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere